Table of Contents Author Guidelines Submit a Manuscript
International Journal of Hepatology
Volume 2012, Article ID 686135, 22 pages
http://dx.doi.org/10.1155/2012/686135
Review Article

Liver Transplantation and Hepatitis C

1Department of Hepato-Biliary-Pancreatic Surgery, Saitama Medical Center, Saitama Medical University, 1981 Tsujido-cho, Kamoda, Kawagoe, Saitama 350-8550, Japan
2Artificial Organ and Transplantation Division, Department of Surgery, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan

Received 9 February 2012; Accepted 21 May 2012

Academic Editor: Mario Reis Alvares-da-Silva

Copyright © 2012 Nobuhisa Akamatsu and Yasuhiko Sugawara. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. Adam, P. McMaster, J. G. O'Grady et al., “Evolution of liver transplantation in Europe. Report of the European Liver Transplant Registry,” Liver Transplantation, vol. 9, no. 12, pp. 1231–1243, 2003. View at Publisher · View at Google Scholar · View at Scopus
  2. R. H. Wiesner, M. Sorrell, F. Villamil et al., “Report of the first international liver transplantation society expert panel consensus conference on liver transplantation and hepatitis C,” Liver Transplantation, vol. 9, no. 11, pp. S1–S9, 2003. View at Publisher · View at Google Scholar · View at Scopus
  3. Y. Sugawara and M. Makuuchi, “Living donor liver transplantation to patients with hepatitis C virus cirrhosis,” World Journal of Gastroenterology, vol. 12, no. 28, pp. 4461–4465, 2006. View at Google Scholar · View at Scopus
  4. M. Berenguer, R. Charco, J. Manuel Pascasio, and J. Ignacio Herrero, “Spanish society of liver transplantation (SETH) consensus recommendations on hepatitis C virus and liver transplantation,” Liver International, vol. 32, no. 5, pp. 712–731, 2012. View at Publisher · View at Google Scholar
  5. M. Garcia-Retortillo, X. Forns, A. Feliu et al., “Hepatitis C virus kinetics during and immediately after liver transplantation,” Hepatology, vol. 35, no. 3, pp. 680–687, 2002. View at Publisher · View at Google Scholar · View at Scopus
  6. M. Berenguer, “Natural history of recurrent hepatitis C,” Liver Transplantation, vol. 8, no. 10, pp. S14–S18, 2002. View at Publisher · View at Google Scholar · View at Scopus
  7. E. J. Gane, B. G. Portmann, N. V. Naoumov et al., “Long-term outcome of hepatitis C infection after liver transplantation,” New England Journal of Medicine, vol. 334, no. 13, pp. 815–820, 1996. View at Publisher · View at Google Scholar · View at Scopus
  8. M. Berenguer, M. Prieto, J. M. Rayón et al., “Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation,” Hepatology, vol. 32, no. 4 I, pp. 852–858, 2000. View at Google Scholar · View at Scopus
  9. T. K. Narang, W. Ahrens, and M. W. Russo, “Post-liver transplant cholestatic hepatitis C: a systematic review of clinical and pathological findings and application of consensus criteria,” Liver Transplantation, vol. 16, no. 11, pp. 1228–1235, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. B. Roche and D. Samuel, “Risk factors for hepatitis C recurrence after liver transplantation,” Journal of Viral Hepatitis, vol. 14, no. 1, supplement, pp. 89–96, 2007. View at Publisher · View at Google Scholar · View at Scopus
  11. L. M. Forman, J. D. Lewis, J. A. Berlin, H. I. Feldman, and M. R. Lucey, “The association between hepatitis C infection and survival after orthotopic liver transplantation,” Gastroenterology, vol. 122, no. 4, pp. 889–896, 2002. View at Google Scholar · View at Scopus
  12. M. Ghabril, R. Dickson, and R. Wiesner, “Improving outcomes of liver retransplantation: an analysis of trends and the impact of hepatitis C infection,” American Journal of Transplantation, vol. 8, no. 2, pp. 404–411, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. M. Berenguer, M. Prieto, F. S. Juan et al., “Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients,” Hepatology, vol. 36, no. 1, pp. 202–210, 2002. View at Publisher · View at Google Scholar · View at Scopus
  14. P. J. Thuluvath, K. L. Krok, D. L. Segev, and H. Y. Yoo, “Trends in post-liver transplant survival in patients with hepatitis C between 1991 and 2001 in the United States,” Liver Transplantation, vol. 13, no. 5, pp. 719–724, 2007. View at Publisher · View at Google Scholar · View at Scopus
  15. L. S. Belli, A. K. Burroughs, P. Burra et al., “Liver transplantation for HCV cirrhosis: improved survival in recent years and increased severity of recurrent disease in female recipients: results of a long term retrospective study,” Liver Transplantation, vol. 13, no. 5, pp. 733–740, 2007. View at Publisher · View at Google Scholar · View at Scopus
  16. M. Berenguer, L. Ferrell, J. Watson et al., “HCV-related fibrosis progression following liver transplantation: increase in recent years,” Journal of Hepatology, vol. 32, no. 4, pp. 673–684, 2000. View at Publisher · View at Google Scholar · View at Scopus
  17. D. Samuel, X. Forns, M. Berenguer et al., “Report of the monothematic EASL conference on liver transplantation for viral hepatitis. (Paris, France, January 12–14, 2006),” Journal of Hepatology, vol. 45, no. 1, pp. 127–143, 2006. View at Publisher · View at Google Scholar · View at Scopus
  18. D. G. Maluf, E. B. Edwards, R. T. Stravitz, and H. M. Kauftman, “Impact of the donor risk index on the outcome of hepatitis C virus-positive Liver transplant recipients,” Liver Transplantation, vol. 15, no. 6, pp. 592–599, 2009. View at Publisher · View at Google Scholar · View at Scopus
  19. M. Wali, R. F. Harrison, P. J. Gow, and D. Mutimer, “Advancing donor liver age and rapid fibrosis progression following transplantation for hepatitis C,” Gut, vol. 51, no. 2, pp. 248–252, 2002. View at Publisher · View at Google Scholar · View at Scopus
  20. K. Rifai, M. Sebagh, V. Karam et al., “Donor age influences 10-year liver graft histology independently of hepatitis C virus infection,” Journal of Hepatology, vol. 41, no. 3, pp. 446–453, 2004. View at Publisher · View at Google Scholar · View at Scopus
  21. J. F. Gallegos-Orozco, A. Yosephy, B. Noble et al., “Natural history of post-liver transplantation hepatitis C: a review of factors that may influence its course,” Liver Transplantation, vol. 15, no. 12, pp. 1872–1881, 2009. View at Publisher · View at Google Scholar · View at Scopus
  22. A. P. Khapra, K. Agarwal, M. I. Fiel et al., “Impact of donor age on survival and fibrosis progression in patients with hepatitis C undergoing liver transplantation using HCV+ allografts,” Liver Transplantation, vol. 12, no. 10, pp. 1496–1503, 2006. View at Publisher · View at Google Scholar · View at Scopus
  23. D. Brandman, A. Pingitore, J. C. Lai et al., “Hepatic steatosis at 1 year is an additional predictor of subsequent fibrosis severity in liver transplant recipients with recurrent hepatitis C virus,” Liver Transplantation, vol. 17, no. 12, pp. 1380–1386, 2011. View at Publisher · View at Google Scholar
  24. S. C. Rayhill, Y. M. Wu, D. A. Katz et al., “Older donor livers show early severe histological activity, fibrosis, and graft failure after liver transplantation for hepatitis C,” Transplantation, vol. 84, no. 3, pp. 331–339, 2007. View at Publisher · View at Google Scholar · View at Scopus
  25. V. I. Machicao, H. Bonatti, M. Krishna et al., “Donor age affects fibrosis progression and graft survival after liver transplantation for hepatitis C,” Transplantation, vol. 77, no. 1, pp. 84–92, 2004. View at Publisher · View at Google Scholar · View at Scopus
  26. N. Selzner, E. L. Renner, M. Selzner et al., “Antiviral treatment of recurrent Hepatitis C after liver transplantation: predictors of response and long-term outcome,” Transplantation, vol. 88, no. 10, pp. 1214–1221, 2009. View at Publisher · View at Google Scholar · View at Scopus
  27. B. Roche, M. Sebagh, M. L. Canfora et al., “Hepatitis C virus therapy in liver transplant recipients: response predictors, effect on fibrosis progression, and importance of the initial stage of fibrosis,” Liver Transplantation, vol. 14, no. 12, pp. 1766–1777, 2008. View at Publisher · View at Google Scholar · View at Scopus
  28. M. Berenguer, V. Aguilera, M. Prieto et al., “Worse recent efficacy of antiviral therapy in liver transplant recipients with recurrent hepatitis C: impact of donor age and baseline cirrhosis,” Liver Transplantation, vol. 15, no. 7, pp. 738–746, 2009. View at Publisher · View at Google Scholar · View at Scopus
  29. M. Hoare, T. Das, and G. Alexander, “Ageing, telomeres, senescence, and liver injury,” Journal of Hepatology, vol. 53, no. 5, pp. 950–961, 2010. View at Publisher · View at Google Scholar · View at Scopus
  30. A. W. Avolio, U. Cillo, M. Salizzoni et al., “Balancing donor and recipient risk factors in liver transplantation: the value of D-MELD with particular reference to HCV recipients,” American Journal of Transplantation, vol. 11, no. 12, pp. 2724–2736, 2011. View at Publisher · View at Google Scholar
  31. P. G. Northup, C. K. Argo, D. T. Nguyen et al., “Liver allografts from hepatitis c positive donors can offer good outcomes in hepatitis C positive recipients: a US national transplant registry analysis,” Transplant International, vol. 23, no. 10, pp. 1038–1044, 2010. View at Publisher · View at Google Scholar · View at Scopus
  32. J. I. Arenas, H. E. Vargas, and J. Rakela, “The use of hepatitis C-infected grafts in liver transplantation,” Liver Transplantation, vol. 9, no. 11, pp. S48–S51, 2003. View at Publisher · View at Google Scholar · View at Scopus
  33. M. Berenguer, “Risk of extended criteria donors in hepatitis C virus-positive recipients,” Liver Transplantation, vol. 14, pp. S45–S50, 2008. View at Google Scholar · View at Scopus
  34. R. Ballarin, A. Cucchetti, M. Spaggiari et al., “Long-term follow-up and outcome of liver transplantation from anti-hepatitis C virus-positive donors: a European multicentric case-control study,” Transplantation, vol. 91, no. 11, pp. 1265–1272, 2011. View at Publisher · View at Google Scholar · View at Scopus
  35. K. D. S. Watt, E. R. Lyden, J. M. Gulizia, and T. M. McCashland, “Recurrent hepatitis C posttransplant: early preservation injury may predict poor outcome,” Liver Transplantation, vol. 12, no. 1, pp. 134–139, 2006. View at Publisher · View at Google Scholar · View at Scopus
  36. P. W. Baron, D. Sindram, D. Higdon et al., “Prolonged rewarming time during allograft implantation predisposes to recurrent hepatitis C infection after liver transplantation,” Liver Transplantation, vol. 6, no. 4, pp. 407–412, 2000. View at Google Scholar · View at Scopus
  37. S. Feng, N. P. Goodrich, J. L. Bragg-Gresham et al., “Characteristics associated with liver graft failure: the concept of a donor risk index,” American Journal of Transplantation, vol. 6, no. 4, pp. 783–790, 2006. View at Publisher · View at Google Scholar · View at Scopus
  38. J. Briceño, R. Ciria, M. Pleguezuelo et al., “Contribution of marginal donors to liver transplantation for hepatitis C virus infection,” Transplantation Proceedings, vol. 39, no. 7, pp. 2297–2299, 2007. View at Publisher · View at Google Scholar · View at Scopus
  39. A. M. Cameron, R. M. Ghobrial, H. Yersiz et al., “Optimal utilization of donor grafts with extended criteria: a single-center experience in over 1000 liver transplants,” Annals of Surgery, vol. 243, no. 6, pp. 748–753, 2006. View at Publisher · View at Google Scholar · View at Scopus
  40. R. Hernandez-Alejandro, K. P. Croome, D. Quan et al., “Increased risk of severe recurrence of hepatitis C virus in liver transplant recipients of donation after cardiac death allografts,” Transplantation, vol. 92, no. 6, pp. 686–689, 2011. View at Publisher · View at Google Scholar
  41. T. Uemura, V. Ramprasad, and C. S. Hollenbeak, “Liver transplantation for hepatitis C from donation after cardiac death donors: an analysis of OPTN/UNOS data,” American Journal of Transplantation, vol. 12, no. 4, pp. 984–991, 2012. View at Google Scholar
  42. S. M. Strasberg, T. K. Howard, E. P. Molmenti, and M. Hertl, “Selecting the donor liver: risk factors for poor function after orthotopic liver transplantation,” Hepatology, vol. 20, no. 4, pp. 829–838, 1994. View at Google Scholar · View at Scopus
  43. R. J. Ploeg, A. M. D'Alessandro, S. J. Knechtle et al., “Risk factors for primary dysfunction after liver transplantation—a multivariate analysis,” Transplantation, vol. 55, no. 4, pp. 807–813, 1993. View at Google Scholar · View at Scopus
  44. A. Nocito, A. M. El-Badry, and P. A. Clavien, “When is steatosis too much for transplantation?” Journal of Hepatology, vol. 45, no. 4, pp. 494–499, 2006. View at Publisher · View at Google Scholar · View at Scopus
  45. V. Subramanian, A. B. Seetharam, and N. Vachharajani, “Donor graft steatosis influences immunity to hepatitis C virus and allograft outcome after liver transplantation,” Transplantation, vol. 92, no. 11, pp. 1259–1268, 2011. View at Google Scholar
  46. M. L. Shiffman, R. T. Stravitz, M. J. Contos et al., “Histologic recurrence of chronic hepatitis C virus in patients after living donor and deceased donor liver transplantation,” Liver Transplantation, vol. 10, no. 10, pp. 1248–1255, 2004. View at Publisher · View at Google Scholar · View at Scopus
  47. M. Schmeding, U. P. Neumann, G. Puhl, M. Bahra, R. Neuhaus, and P. Neuhaus, “Hepatitis C recurrence and fibrosis progression are not increased after living donor liver transplantation: a single-center study of 289 patients,” Liver Transplantation, vol. 13, no. 5, pp. 687–692, 2007. View at Publisher · View at Google Scholar · View at Scopus
  48. A. Humar, K. Horn, A. Kalis, B. Glessing, W. D. Payne, and J. Lake, “Living donor and split-liver transplants in hepatitis C recipients: does liver regeneration increase the risk for recurrence?” American Journal of Transplantation, vol. 5, no. 2, pp. 399–405, 2005. View at Publisher · View at Google Scholar · View at Scopus
  49. L. Guo, M. Orrego, H. Rodriguez-Luna et al., “Living donor liver transplantation for hepatitis C-related cirrhosis: no difference in histological recurrence when compared to deceased donor liver transplantation recipients,” Liver Transplantation, vol. 12, no. 4, pp. 560–565, 2006. View at Publisher · View at Google Scholar · View at Scopus
  50. N. A. Terrault, M. L. Shiffman, A. S. F. Lok et al., “Outcomes in hepatitis C virus-infected recipients of living donor vs. deceased donor liver transplantation,” Liver Transplantation, vol. 13, no. 1, pp. 122–129, 2007. View at Publisher · View at Google Scholar · View at Scopus
  51. C. Feray, L. Caccamo, and G. J. Alexander, “European collaborative study on factors influencing outcome after liver transplantation for hepatitis C. European Concerted Action on Viral Hepatitis (EUROHEP) Group,” Gastroenterology, vol. 117, no. 3, pp. 619–625, 1999. View at Google Scholar
  52. H. E. Vargas, T. Laskus, L. F. Wang et al., “The influence of hepatitis C virus genotypes on the outcome of liver transplantation,” Liver Transplantation and Surgery, vol. 4, no. 1, pp. 22–27, 1998. View at Google Scholar · View at Scopus
  53. M. Berenguer, J. Crippin, R. Gish et al., “A model to predict severe HCV-related disease following liver transplantation,” Hepatology, vol. 38, no. 1, pp. 34–41, 2003. View at Publisher · View at Google Scholar · View at Scopus
  54. M. Charlton, E. Seaberg, R. Wiesner et al., “Predictors of patient and graft survival following liver transplantation for hepatitis C,” Hepatology, vol. 28, no. 3, pp. 823–830, 1998. View at Google Scholar · View at Scopus
  55. R. Sreekumar, A. Gonzalez-Koch, Y. Maor-Kendler et al., “Early identification of recipients with progressive histologic recurrence of hepatitis C after liver transplantation,” Hepatology, vol. 32, no. 5, pp. 1125–1130, 2000. View at Google Scholar · View at Scopus
  56. G. W. McCaughan and A. Zekry, “Mechanisms of HCV reinfection and allograft damage after liver transplantation,” Journal of Hepatology, vol. 40, no. 3, pp. 368–374, 2004. View at Publisher · View at Google Scholar · View at Scopus
  57. A. L. Doughty, D. M. Painter, and G. W. McCaughan, “Post-transplant quasispecies pattern remains stable over time in patients with recurrent cholestatic hepatitis due to hepatitis C virus,” Journal of Hepatology, vol. 32, no. 1, pp. 126–134, 2000. View at Google Scholar · View at Scopus
  58. A. C. Lyra, X. Fan, D. M. Lang et al., “Evolution of hepatitis C viral quasispecies after liver transplantation,” Gastroenterology, vol. 123, no. 5, pp. 1485–1493, 2002. View at Google Scholar · View at Scopus
  59. M. Selzner, A. Kashfi, N. Selzner et al., “Recipient age affects long-term outcome and hepatitis C recurrence in old donor livers following transplantation,” Liver Transplantation, vol. 15, no. 10, pp. 1288–1295, 2009. View at Publisher · View at Google Scholar · View at Scopus
  60. R. J. Firpi, M. F. Abdelmalek, C. Soldevila-Pico et al., “One-year protocol liver biopsy can stratify fibrosis progression in liver transplant recipients with recurrent hepatitis C infection,” Liver Transplantation, vol. 10, no. 10, pp. 1240–1247, 2004. View at Publisher · View at Google Scholar · View at Scopus
  61. P. S. Pang, A. Kamal, and J. S. Glenn, “The effect of donor race on the survival of black Americans undergoing liver transplantation for chronic hepatitis C,” Liver Transplantation, vol. 15, no. 9, pp. 1126–1132, 2009. View at Publisher · View at Google Scholar · View at Scopus
  62. V. Saxena, J. C. Lai, J. G. O'Leary et al., “Recipient-donor race mismatch for African American liver transplant patients with chronic hepatitis C,” Liver Transpl, vol. 18, no. 5, pp. 524–531, 2012. View at Google Scholar
  63. M. Moeller, A. Zalawadia, A. Alrayes, G. Divine, K. Brown, and D. Moonka, “The impact of donor race on recurrent hepatitis C after liver transplantation,” Transplantation Proceedings, vol. 42, no. 10, pp. 4175–4177, 2010. View at Publisher · View at Google Scholar · View at Scopus
  64. T. Walter, J. Dumortier, O. Guillaud, V. Hervieu, J. Y. Scoazec, and O. Boillot, “Factors influencing the progression of fibrosis in patients with recurrent hepatitis C after liver transplantation under antiviral therapy: a retrospective analysis of 939 liver biopsies in a single center,” Liver Transplantation, vol. 13, no. 2, pp. 294–301, 2007. View at Publisher · View at Google Scholar · View at Scopus
  65. J. C. Lai, E. C. Verna, R. S. Brown et al., “Hepatitis c virus-infected women have a higher risk of advanced fibrosis and graft loss after liver transplantation than men,” Hepatology, vol. 54, no. 2, pp. 418–424, 2011. View at Publisher · View at Google Scholar · View at Scopus
  66. M. R. Charlton, A. Thompson, B. J. Veldt et al., “Interleukin-28B polymorphisms are associated with histological recurrence and treatment response following liver transplantation in patients with hepatitis C virus infection,” Hepatology, vol. 53, no. 1, pp. 317–324, 2011. View at Publisher · View at Google Scholar · View at Scopus
  67. C. M. Lange, D. Moradpour, A. Doehring et al., “Impact of donor and recipient IL28B rs12979860 genotypes on hepatitis C virus liver graft reinfection,” Journal of Hepatology, vol. 55, no. 2, pp. 322–327, 2011. View at Publisher · View at Google Scholar · View at Scopus
  68. T. Fukuhara, A. Taketomi, T. Motomura et al., “Variants in IL28B in liver recipients and donors correlate with response to peg-interferon and ribavirin therapy for recurrent hepatitis C,” Gastroenterology, vol. 139, no. 5, pp. 1577–1585, 2010. View at Publisher · View at Google Scholar · View at Scopus
  69. M. Coto-Llerena, G. Crespo, P. González et al., “Determination of IL28B polymorphisms in liver biopsies obtained after liver transplantation,” Journal of Hepatology, vol. 56, no. 2, pp. 355–358, 2012. View at Publisher · View at Google Scholar
  70. E. C. Verna, E. De Martin, P. Burra et al., “The impact of hepatitis C and biliary complications on patient and graft survival following liver transplantation,” American Journal of Transplantation, vol. 9, no. 6, pp. 1398–1405, 2009. View at Publisher · View at Google Scholar · View at Scopus
  71. A. Bozorgzadeh, M. Orloff, P. Abt et al., “Survival outcomes in liver transplantation for hepatocellular carcinoma, comparing impact of hepatitis C versus other etiology of cirrhosis,” Liver Transplantation, vol. 13, no. 6, pp. 807–813, 2007. View at Publisher · View at Google Scholar · View at Scopus
  72. A. Moya, M. Berenguer, V. Aguilera et al., “Hepatocellular carcinoma: can it be considered a controversial indication for liver transplantation in centers with high rates of hepatitis C?” Liver Transplantation, vol. 8, no. 11, pp. 1020–1027, 2002. View at Publisher · View at Google Scholar · View at Scopus
  73. R. J. Firpi, V. Clark, C. Soldevila-Pico et al., “The natural history of hepatitis C cirrhosis after liver transplantation,” Liver Transplantation, vol. 15, no. 9, pp. 1063–1071, 2009. View at Publisher · View at Google Scholar · View at Scopus
  74. K. H. W. Böker, G. Dalley, M. J. Bahr et al., “Long-term outcome of hepatitis C virus infection after liver transplantation,” Hepatology, vol. 25, no. 1, pp. 203–210, 1997. View at Google Scholar · View at Scopus
  75. E. Melum, S. Friman, K. Bjøro et al., “Hepatitis C impairs survival following liver transplantation irrespective of concomitant hepatocellular carcinoma,” Journal of Hepatology, vol. 47, no. 6, pp. 777–783, 2007. View at Publisher · View at Google Scholar · View at Scopus
  76. D. N. Samonakis, C. K. Triantos, U. Thalheimer et al., “Immunosuppresion and donor age with respect to severity of HCV recurrence after liver transplantation,” Liver Transplantation, vol. 11, no. 4, pp. 386–395, 2005. View at Publisher · View at Google Scholar · View at Scopus
  77. Y. Sugawara, S. Tamura, and N. Kokudo, “Liver transplantation in HCV/HIV positive patients,” World Journal of Gastrointestinal Surgery, vol. 3, no. 2, pp. 21–28, 2011. View at Google Scholar
  78. J. C. Duclos-Vallee, B. Falissard, and D. Samuel, “Liver transplant outcomes in HIV-infected patients: a systematic review and meta-analysis with a synthetic cohort,” AIDS, vol. 25, no. 13, pp. 1675–1676, 2011. View at Google Scholar
  79. J. C. Duclos-Vallee, C. Feray, and M. Sebagh, “Survival and recurrence of hepatitis C after liver transplantation in patients coinfected with human immunodeficiency virus and hepatitis C virus,” Hepatology, vol. 47, no. 2, pp. 407–417, 2008. View at Google Scholar
  80. A. Moreno, C. Cervera, J. Fortun et al., “Epidemiology and outcome of infections in human immunodeficiency virus/hepatitis c virus-coinfected liver transplant recipients: a FIPSE/GESIDA Prospective Cohort Study,” Liver Transplantation, vol. 18, no. 1, pp. 70–81, 2012. View at Google Scholar
  81. M. E. De Vera, I. Dvorchik, K. Tom et al., “Survival of liver transplant patients coinfected with HIV and HCV is adversely impacted by recurrent hepatitis C,” American Journal of Transplantation, vol. 6, no. 12, pp. 2983–2993, 2006. View at Publisher · View at Google Scholar · View at Scopus
  82. J. Fung, B. Eghtesad, K. Patel-Tom, M. DeVera, H. Chapman, and M. Ragni, “Liver transplantation in patients with HIV infection,” Liver Transplantation, vol. 10, no. 10, supplement, pp. S39–S53, 2004. View at Publisher · View at Google Scholar · View at Scopus
  83. K. Wojcik, M. Vogel, E. Voigt et al., “Antiviral therapy for hepatitis C virus recurrence after liver transplantation in HIV-infected patients: outcome in the Bonn cohort,” AIDS, vol. 21, no. 10, pp. 1363–1365, 2007. View at Publisher · View at Google Scholar · View at Scopus
  84. N. M. Kemmer and K. E. Sherman, “Liver transplantation trends in the HIV population,” Digestive Diseases and Sciences, vol. 56, no. 11, pp. 3393–3398, 2011. View at Google Scholar
  85. E. J. Gane, N. V. Naoumov, K. P. Qian et al., “A longitudinal analysis of hepatitis C virus replication following liver transplantation,” Gastroenterology, vol. 110, no. 1, pp. 167–177, 1996. View at Publisher · View at Google Scholar · View at Scopus
  86. I. A. Hanouneh, A. E. Feldstein, A. J. McCullough et al., “The significance of metabolic syndrome in the setting of recurrent hepatitis C after liver transplantation,” Liver Transplantation, vol. 14, no. 9, pp. 1287–1293, 2008. View at Publisher · View at Google Scholar · View at Scopus
  87. G. V. Papatheodoridis, S. G. R. G. Barton, D. Andrew et al., “Longitudinal variation in hepatitis C virus (HCV) viraemia and early course of HCV infection after liver transplantation for HCV cirrhosis: the role of different immunosuppressive regimens,” Gut, vol. 45, no. 3, pp. 427–434, 1999. View at Google Scholar · View at Scopus
  88. N. A. Shackel, J. Jamias, W. Rahman et al., “Early high peak hepatitis C viral load levels independently predict hepatitis C-related liver failure post-liver transplantation,” Liver Transplantation, vol. 15, no. 7, pp. 709–718, 2009. View at Publisher · View at Google Scholar · View at Scopus
  89. H. R. Rosen, S. Chou, C. L. Corless et al., “Cytomegalovirus viremia: risk factor for allograft cirrhosis after liver transplantation for hepatitis C,” Transplantation, vol. 64, no. 5, pp. 721–726, 1997. View at Publisher · View at Google Scholar · View at Scopus
  90. K. W. Burak, W. K. Kremers, K. P. Batts et al., “Impact of cytomegalovirus infection, year of transplantation, and donor age on outcomes after liver transplantation for hepatitis C,” Liver Transplantation, vol. 8, no. 4, pp. 362–369, 2002. View at Publisher · View at Google Scholar · View at Scopus
  91. A. Humara, D. Kumar, J. Raboud et al., “Interactions between cytomegalovirus, human herpesvirus-6, and the recurrence of hepatitis C after liver transplantation,” American Journal of Transplantation, vol. 2, no. 5, pp. 461–466, 2002. View at Publisher · View at Google Scholar · View at Scopus
  92. R. Teixeira, S. Pastacaldi, S. Davies et al., “The influence of cytomegalovirus viraemia on the outcome of recurrent hepatitis C after liver transplantation,” Transplantation, vol. 70, no. 10, pp. 1454–1458, 2000. View at Google Scholar · View at Scopus
  93. S. Baid, A. B. Cosimi, M. Lin Farrell et al., “Posttransplant diabetes mellitus in liver transplant recipients: risk factors, temporal, relationship with hepatitis C virus allograft hepatitis, and impact on mortality,” Transplantation, vol. 72, no. 6, pp. 1066–1072, 2001. View at Google Scholar · View at Scopus
  94. M. R. Foxton, A. Quaglia, R. Muiesan et al., “The impact of diabetes mellitus on fibrosis progression in patients transplanted for hepatitis C,” American Journal of Transplantation, vol. 6, no. 8, pp. 1922–1929, 2006. View at Publisher · View at Google Scholar · View at Scopus
  95. A. A. AlDosary, A. S. Ramji, T. G. Elliott et al., “Post-liver transplantation diabetes mellitus: an association with hepatitis C,” Liver Transplantation, vol. 8, no. 4, pp. 356–361, 2002. View at Publisher · View at Google Scholar · View at Scopus
  96. E. J. Gane, “Diabetes mellitus following liver transplantation in patients with hepatitis C virus: risks and consequences,” American Journal of Transplantation, vol. 12, no. 3, pp. 531–538, 2012. View at Publisher · View at Google Scholar
  97. S. G. Tueche, “Diabetes mellitus after liver transplant new etiologic clues and cornerstones for understanding,” Transplantation Proceedings, vol. 35, no. 4, pp. 1466–1468, 2003. View at Publisher · View at Google Scholar · View at Scopus
  98. K. C. Abbott, K. L. Lentine, J. R. Bucci et al., “Impact of diabetes and hepatitis after kidney transplantation on patients who are affected by hepatitis C virus,” Journal of the American Society of Nephrology, vol. 15, no. 12, pp. 3166–3174, 2004. View at Publisher · View at Google Scholar · View at Scopus
  99. B. J. Veldt, J. J. Poterucha, K. D. S. Watt et al., “Insulin resistance, serum adipokines and risk of fibrosis progression in patients transplanted for hepatitis C,” American Journal of Transplantation, vol. 9, no. 6, pp. 1406–1413, 2009. View at Publisher · View at Google Scholar · View at Scopus
  100. J. R. Lake, “The role of immunosuppression in recurrence of hepatitis C,” Liver Transplantation, vol. 9, no. 11, pp. S63–S66, 2003. View at Publisher · View at Google Scholar · View at Scopus
  101. P. A. Sheiner, M. E. Schwartz, E. Mor et al., “Severe or multiple rejection episodes are associated with early recurrence of hepatitis C after orthotopic liver transplantation,” Hepatology, vol. 21, no. 1, pp. 30–34, 1995. View at Google Scholar · View at Scopus
  102. M. Charlton and E. Seaberg, “Impact of immunosuppression and acute rejection on recurrence of hepatitis C: results of the national institute of diabetes and digestive and kidney diseases liver transplantation database,” Liver Transplantation and Surgery, vol. 5, no. 4, supplement 1, pp. S107–S114, 1999. View at Google Scholar · View at Scopus
  103. U. P. Neumann, T. Berg, M. Bahra et al., “Long-term outcome of liver transplants for chronic hepatitis C: a 10-year follow-up,” Transplantation, vol. 77, no. 2, pp. 226–231, 2004. View at Publisher · View at Google Scholar · View at Scopus
  104. S. Mukherjee and M. F. Sorrell, “Controversies in liver transplantation for hepatitis C,” Gastroenterology, vol. 134, no. 6, pp. 1777–1788, 2008. View at Publisher · View at Google Scholar · View at Scopus
  105. M. Berenguer, V. Aguilera, M. Prieto et al., “Significant improvement in the outcome of HCV-infected transplant recipients by avoiding rapid steroid tapering and potent induction immunosuppression,” Journal of Hepatology, vol. 44, no. 4, pp. 717–722, 2006. View at Publisher · View at Google Scholar · View at Scopus
  106. S. Brillanti, M. Vivarelli, N. De Ruvo et al., “Slowly tapering off steroids protects the graft against hepatitis C recurrence after liver transplantation,” Liver Transplantation, vol. 8, no. 10, pp. 884–888, 2002. View at Publisher · View at Google Scholar · View at Scopus
  107. M. Vivarelli, P. Burra, G. L. Barba et al., “Influence of steroids on HCV recurrence after liver transplantation: a prospective study,” Journal of Hepatology, vol. 47, no. 6, pp. 793–798, 2007. View at Publisher · View at Google Scholar · View at Scopus
  108. G. Sgourakis, A. Radtke, I. Fouzas et al., “Corticosteroid-free immunosuppression in liver transplantation: a meta-analysis and meta-regression of outcomes,” Transplant International, vol. 22, no. 9, pp. 892–905, 2009. View at Publisher · View at Google Scholar · View at Scopus
  109. J. D. Eason, S. Nair, A. J. Cohen, J. L. Blazek, and G. E. Loss, “Steroid-free liver transplantation using rabbit antithymocyte globulin and early tacrolimus monotherapy,” Transplantation, vol. 75, no. 8, pp. 1396–1399, 2003. View at Publisher · View at Google Scholar · View at Scopus
  110. C. Margarit, I. Bilbao, L. Castells et al., “A prospective randomized trial comparing tacrolimus and steroids with tacrolimus monotherapy in liver transplantation: the impact on recurrence of hepatitis C,” Transplant International, vol. 18, no. 12, pp. 1336–1345, 2005. View at Publisher · View at Google Scholar · View at Scopus
  111. T. Kato, J. J. Gaynor, H. Yoshida et al., “Randomized trial of steroid-free induction versus corticosteroid maintenance among orthotopic liver transplant recipients with hepatitis C virus: impact on hepatic fibrosis progression at one year,” Transplantation, vol. 84, no. 7, pp. 829–835, 2007. View at Publisher · View at Google Scholar · View at Scopus
  112. L. Lladó, J. Fabregat, J. Castellote et al., “Impact of immunosuppression without steroids on rejection and hepatitis C virus evolution after liver transplantation: results of a prospective randomized study,” Liver Transplantation, vol. 14, no. 12, pp. 1752–1760, 2008. View at Publisher · View at Google Scholar · View at Scopus
  113. F. Filipponi, F. Callea, M. Salizzoni et al., “Double-blind comparison of hepatitis C histological recurrence rate in HCV+ Liver Transplant Recipients Given Basiliximab+Steroids or Basiliximab+Placebo, in addition to Cyclosporine and Azathioprine,” Transplantation, vol. 78, no. 10, pp. 1488–1495, 2004. View at Publisher · View at Google Scholar · View at Scopus
  114. D. L. Segev, S. M. Sozio, E. J. Shin et al., “Steroid avoidance in liver transplantation: meta-analysis and meta-regression of randomized trials,” Liver Transplantation, vol. 14, no. 4, pp. 512–525, 2008. View at Publisher · View at Google Scholar · View at Scopus
  115. P. Manousou, D. Samonakis, E. Cholongitas et al., “Outcome of recurrent hepatitis C virus after liver transplantation in a randomized trial of tacrolimus monotherapy versus triple therapy,” Liver Transplantation, vol. 15, no. 12, pp. 1783–1791, 2009. View at Publisher · View at Google Scholar · View at Scopus
  116. G. B. Klintmalm, G. L. Davis, and L. Teperman, “A randomized, multicenter study comparing steroid-free immunosuppression and standard immunosuppression for liver transplant recipients with chronic hepatitis C,” Liver Transplantation, vol. 17, no. 12, pp. 1394–1403, 2011. View at Google Scholar
  117. M. Nakagawa, N. Sakamoto, and N. Enomoto, “Specific inhibition of hepatitis C virus replication by cyclosporin A,” Biochemical and Biophysical Research Communications, vol. 313, no. 1, pp. 42–47, 2004. View at Google Scholar
  118. S. D. Henry, H. J. Metselaar, R. C. B. Lonsdale et al., “Mycophenolic acid inhibits hepatitis C virus replication and acts in synergy with cyclosporin A and interferon-α,” Gastroenterology, vol. 131, no. 5, pp. 1452–1462, 2006. View at Publisher · View at Google Scholar · View at Scopus
  119. K. Watashi, M. Hijikata, M. Hosaka, M. Yamaji, and K. Shimotohno, “Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes,” Hepatology, vol. 38, no. 5, pp. 1282–1288, 2003. View at Publisher · View at Google Scholar · View at Scopus
  120. R. D. Kim, S. Mizuno, J. B. Sorensen, J. J. Schwartz, and S. Fujita, “Impact of calcineurin inhibitors on hepatitis C recurrence after liver transplantation,” Digestive Diseases and Sciences, vol. 57, no. 2, pp. 568–572, 2012. View at Publisher · View at Google Scholar
  121. R. J. Firpi, H. Zhu, G. Morelli et al., “Cyclosporine suppresses hepatitis C virus in vitro and increases the chance of a sustained virological response after liver transplantation,” Liver Transplantation, vol. 12, no. 1, pp. 51–57, 2006. View at Publisher · View at Google Scholar · View at Scopus
  122. R. J. Firpi, C. Soldevila-Pico, G. G. Morelli et al., “The use of cyclosporine for recurrent hepatitis C after liver transplant: a randomized pilot study,” Digestive Diseases and Sciences, vol. 55, no. 1, pp. 196–203, 2010. View at Publisher · View at Google Scholar · View at Scopus
  123. L. J. W. Van Der Laan, M. Hudson, S. McPherson et al., “Results of a two-center study comparing hepatic fibrosis progression in HCV-positive liver transplant patients receiving cyclosporine or tacrolimus,” Transplantation Proceedings, vol. 42, no. 10, pp. 4573–4577, 2010. View at Publisher · View at Google Scholar · View at Scopus
  124. L. C. Fusté, “Cyclosporine a-based immunosuppression reduces relapse rate after antiviral therapy in transplanted patients with hepatitis C virus infection: a large multicenter cohort study,” Transplantation, vol. 92, no. 3, pp. 334–340, 2011. View at Publisher · View at Google Scholar · View at Scopus
  125. P. Martin, R. W. Busuttil, R. M. Goldstein et al., “Impact of tacrolimus versus cyclosporine in hepatitis C virus-infected liver transplant recipients on recurrent hepatitis: a prospective, randomized trial,” Liver Transplantation, vol. 10, no. 10, pp. 1258–1262, 2004. View at Publisher · View at Google Scholar · View at Scopus
  126. J. G. O'Grady, P. Hardy, A. K. Burroughs et al., “Randomized controlled trial of tacrolimus versus microemulsified cyclosporin (TMC) in liver transplantation: poststudy surveillance to 3 years,” American Journal of Transplantation, vol. 7, no. 1, pp. 137–141, 2007. View at Publisher · View at Google Scholar · View at Scopus
  127. G. Levy, G. L. Grazi, and F. Sanjuan, “12-month follow-up analysis of a multicenter, randomized, prospective trial in de novo liver transplant recipients (LIS2T) comparing cyclosporine microemulsion (C2 monitoring) and tacrolimus,” Liver Transplantation, vol. 12, no. 10, pp. 1464–1472, 2006. View at Google Scholar
  128. M. Berenguer, V. Aguilera, F. San Juan et al., “Effect of calcineurin inhibitors in the outcome of liver transplantation in hepatitis C virus-positive recipients,” Transplantation, vol. 90, no. 11, pp. 1204–1209, 2010. View at Publisher · View at Google Scholar · View at Scopus
  129. M. Berenguer, A. Royuela, and J. Zamora, “Immunosuppression with calcineurin inhibitors with respect to the outcome of HCV recurrence after liver transplantation: results of a meta-analysis,” Liver Transplantation, vol. 13, no. 1, pp. 21–29, 2007. View at Publisher · View at Google Scholar · View at Scopus
  130. W. D. Irish, S. Arcona, D. Bowers, and J. F. Trotter, “Cyclosporine versus tacrolimus treated liver transplant recipients with chronic hepatitis C: outcomes analysis of the UNOS/OPTN database,” American Journal of Transplantation, vol. 11, no. 8, pp. 1676–1685, 2011. View at Publisher · View at Google Scholar · View at Scopus
  131. H. R. Rosen, C. R. Shackleton, L. Higa et al., “Use of OKT3 is associated with early and severe recurrence of hepatitis C after liver transplantation,” American Journal of Gastroenterology, vol. 92, no. 9, pp. 1453–1457, 1997. View at Google Scholar · View at Scopus
  132. A. Marcos, B. Eghtesad, J. J. Fung et al., “Use of alemtuzumab and tacrolimus monotherapy for cadaveric liver transplantation: with particular reference to hepatitis C virus,” Transplantation, vol. 78, no. 7, pp. 966–971, 2004. View at Publisher · View at Google Scholar · View at Scopus
  133. S. Nair, G. E. Loss, A. J. Cohen, and J. D. Eason, “Induction with rabbit antithymocyte globulin versus induction with corticosteroids in liver transplantation: impact on recurrent hepatitis C virus infection,” Transplantation, vol. 81, no. 4, pp. 620–622, 2006. View at Publisher · View at Google Scholar · View at Scopus
  134. N. De Ruvo, A. Cucchetti, A. Lauro et al., “Preliminary results of a “prope” tolerogenic regimen with thymoglobulin pretreatment and hepatitis C virus recurrence in liver transplantation,” Transplantation, vol. 80, no. 1, pp. 8–12, 2005. View at Publisher · View at Google Scholar · View at Scopus
  135. Y. Calmus, J. R. Scheele, I. Gonzalez-Pinto et al., “Immunoprophylaxis with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with azathioprine-containing triple therapy in liver transplant recipients,” Liver Transplantation, vol. 8, no. 2, pp. 123–131, 2002. View at Publisher · View at Google Scholar · View at Scopus
  136. G. B. G. Klintmalm, W. K. Washburn, S. M. Rudich et al., “Corticosteroid-free immunosuppression with daclizumab in HCV+ liver transplant recipients: 1-year interim results of the HCV-3 study,” Liver Transplantation, vol. 13, no. 11, pp. 1521–1531, 2007. View at Publisher · View at Google Scholar · View at Scopus
  137. P. Neuhaus, P. A. Clavien, D. Kittur et al., “Improved treatment response with basiliximab immunoprophylaxis after liver transplantation: results from a double-blind randomized placebo-controlled trial,” Liver Transplantation, vol. 8, no. 2, pp. 132–142, 2002. View at Publisher · View at Google Scholar · View at Scopus
  138. D. R. Nelson, C. Soldevila-Pico, A. Reed et al., “Anti-interleukin-2 receptor therapy in combination with mycophenolate mofetil is associated with more severe hepatitis C recurrence after liver transplantation,” Liver Transplantation, vol. 7, no. 12, pp. 1064–1070, 2001. View at Publisher · View at Google Scholar · View at Scopus
  139. A. Jain, R. Kashyap, A. J. Demetris, B. Eghstesad, R. Pokharna, and J. J. Fung, “A prospective randomized trial of mycophenolate mofetil in liver transplant recipients with hepatitis C,” Liver Transplantation, vol. 8, no. 1, pp. 40–46, 2002. View at Publisher · View at Google Scholar · View at Scopus
  140. R. H. Wiesner, J. S. Shorr, B. J. Steffen, A. H. Chu, R. D. Gordon, and J. R. Lake, “Mycophenolate mofetil combination therapy improves long-term outcomes after liver transplantation in patients with and without hepatitis C,” Liver Transplantation, vol. 11, no. 7, pp. 750–759, 2005. View at Publisher · View at Google Scholar · View at Scopus
  141. F. Sánchez-Bueno, M. L. Ortiz, J. Bermejo et al., “Prognostic factors for hepatitis C recurrence in patients undergoing orthotopic liver transplantation,” Transplant Immunology, vol. 17, no. 1, pp. 47–50, 2006. View at Publisher · View at Google Scholar · View at Scopus
  142. T. M. Manzia, R. Angelico, L. Toti et al., “Long-term, maintenance MMF monotherapy improves the fibrosis progression in liver transplant recipients with recurrent hepatitis C,” Transplant International, vol. 24, no. 5, pp. 461–468, 2011. View at Publisher · View at Google Scholar · View at Scopus
  143. A. Kornberg, B. Küpper, A. Tannapfel, M. Hommann, and J. Scheele, “Impact of mycophenolate mofetil versus azathioprine on early recurrence of hepatitis C after liver transplantation,” International Immunopharmacology, vol. 5, no. 1, pp. 107–115, 2005. View at Publisher · View at Google Scholar · View at Scopus
  144. A. Kornberg, B. Küpper, J. Wilberg et al., “Conversion to mycophenolate mofetil for modulating recurrent hepatitis C in liver transplant recipients,” Transplant Infectious Disease, vol. 9, no. 4, pp. 295–301, 2007. View at Publisher · View at Google Scholar · View at Scopus
  145. M. Bahra, U. I. F. P. Neumann, D. Jacob et al., “MMF and calcineurin taper in recurrent hepatitis C after liver transplantation: impact on histological course,” American Journal of Transplantation, vol. 5, no. 2, pp. 406–411, 2005. View at Publisher · View at Google Scholar · View at Scopus
  146. A. Zekry, M. Gleeson, S. Guney, and G. W. McCaughan, “A prospective cross-over study comparing the effect of mycophenolate versus azathioprine on allograft function and viral load in liver transplant recipients with recurrent chronic HCV infection,” Liver Transplantation, vol. 10, no. 1, pp. 52–57, 2004. View at Publisher · View at Google Scholar · View at Scopus
  147. G. Germani, M. Pleguezuelo, F. Villamil et al., “Azathioprine in liver transplantation: a reevaluation of its use and a comparison with mycophenolate mofetil,” American Journal of Transplantation, vol. 9, no. 8, pp. 1725–1731, 2009. View at Publisher · View at Google Scholar · View at Scopus
  148. T. Kawahara, S. Asthana, and N. M. Kneteman, “m-TOR inhibitors: what role in liver transplantation?” Journal of Hepatology, vol. 55, no. 6, pp. 1441–1451, 2011. View at Google Scholar
  149. S. Asthana, C. Toso, G. Meeberg et al., “The impact of sirolimus on hepatitis C recurrence after liver transplantation,” Canadian Journal of Gastroenterology, vol. 25, no. 1, pp. 28–34, 2011. View at Google Scholar · View at Scopus
  150. S. J. F. Harper, W. Gelson, I. G. Harper, G. J. M. Alexander, and P. Gibbs, “Switching to sirolimus-based immune suppression after liver transplantation is safe and effective: a single-center experience,” Transplantation, vol. 91, no. 1, pp. 128–132, 2011. View at Publisher · View at Google Scholar · View at Scopus
  151. H. R. Rosen, D. R. Gretch, M. Oehlke et al., “Timing and severity of initial hepatitis C recurrence as predictors of long-term liver allograft injury,” Transplantation, vol. 65, no. 9, pp. 1178–1182, 1998. View at Publisher · View at Google Scholar · View at Scopus
  152. M. Prieto, M. Berenguer, J. M. Rayón et al., “High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: relationship with rejection episodes,” Hepatology, vol. 29, no. 1, pp. 250–256, 1999. View at Publisher · View at Google Scholar · View at Scopus
  153. A. Sánchez-Fueyo, J. C. Restrepo, L. Quintó et al., “Impact of the recurrence of hepatitis c virus infection after liver transplantation on the long-term viability of the graft,” Transplantation, vol. 73, no. 1, pp. 56–63, 2002. View at Google Scholar · View at Scopus
  154. M. Guido, S. Fagiuoli, G. Tessari et al., “Histology predicts cirrhotic evolution of post transplant hepatitis C,” Gut, vol. 50, no. 5, pp. 697–700, 2002. View at Publisher · View at Google Scholar · View at Scopus
  155. G. Testa, J. S. Crippin, G. J. Netto et al., “Liver transplantation for hepatitis C: recurrence and disease progression in 300 patients,” Liver Transplantation, vol. 6, no. 5, pp. 553–561, 2000. View at Google Scholar · View at Scopus
  156. M. Berenguer, J. M. Rayón, M. Prieto et al., “Are posttransplantation protocol liver biopsies useful in the long term?” Liver Transplantation, vol. 7, no. 9, pp. 790–796, 2001. View at Publisher · View at Google Scholar · View at Scopus
  157. M. Sebagh, K. Rifai, C. Féray et al., “All liver recipients benefit from the protocol 10-year liver biopsies,” Hepatology, vol. 37, no. 6, pp. 1293–1301, 2003. View at Publisher · View at Google Scholar · View at Scopus
  158. A. Blasco, X. Forns, J. A. Carrión et al., “Hepatic venous pressure gradient identifies patients at risk of severe hepatitis C recurrence after liver transplantation,” Hepatology, vol. 43, no. 3, pp. 492–499, 2006. View at Publisher · View at Google Scholar · View at Scopus
  159. D. N. Samonakis, E. Cholongitas, U. Thalheimer et al., “Hepatic venous pressure gradient to assess fibrosis and its progression after liver transplantation for HCV cirrhosis,” Liver Transplantation, vol. 13, no. 9, pp. 1305–1311, 2007. View at Publisher · View at Google Scholar · View at Scopus
  160. G. Kalambokis, P. Manousou, D. Samonakis et al., “Clinical outcome of HCV-related graft cirrhosis and prognostic value of hepatic venous pressure gradient,” Transplant International, vol. 22, no. 2, pp. 172–181, 2009. View at Publisher · View at Google Scholar · View at Scopus
  161. E. Cholongitas, E. Tsochatzis, J. Goulis, and A. K. Burroughs, “Noninvasive tests for evaluation of fibrosis in HCV recurrence after liver transplantation: a systematic review,” Transplant International, vol. 23, no. 9, pp. 861–870, 2010. View at Publisher · View at Google Scholar · View at Scopus
  162. C. Kamphues, K. Lotz, C. Röcken et al., “Chances and limitations of non-invasive tests in the assessment of liver fibrosis in liver transplant patients,” Clinical Transplantation, vol. 24, no. 5, pp. 652–659, 2010. View at Publisher · View at Google Scholar · View at Scopus
  163. J. A. Carrión, M. Navasa, J. Bosch, M. Bruguera, R. Gilabert, and X. Forns, “Transient elastography for diagnosis of advanced fibrosis and portal hypertension in patients with hepatitis C recurrence after liver transplantation,” Liver Transplantation, vol. 12, no. 12, pp. 1791–1798, 2006. View at Publisher · View at Google Scholar · View at Scopus
  164. C. Rigamonti, M. F. Donato, M. Fraquelli et al., “Transient elastography predicts fibrosis progression in patients with recurrent hepatitis C after liver transplantation,” Gut, vol. 57, no. 6, pp. 821–827, 2008. View at Publisher · View at Google Scholar · View at Scopus
  165. F. Corradi, F. Piscaglia, S. Flori et al., “Assessment of liver fibrosis in transplant recipients with recurrent HCV infection: usefulness of transient elastography,” Digestive and Liver Disease, vol. 41, no. 3, pp. 217–225, 2009. View at Publisher · View at Google Scholar · View at Scopus
  166. N. Harada, Y. Soejima, A. Taketomi et al., “Assessment of graft fibrosis by transient elastography in patients with recurrent hepatitis C after living donor liver transplantation,” Transplantation, vol. 85, no. 1, pp. 69–74, 2008. View at Publisher · View at Google Scholar · View at Scopus
  167. J. A. Carríon, F. Torres, G. Crespo et al., “Liver stiffness identifies two different patterns of fibrosis progression in patients with hepatitis C virus recurrence after liver transplantation,” Hepatology, vol. 51, no. 1, pp. 23–34, 2010. View at Publisher · View at Google Scholar · View at Scopus
  168. V. S. Lee, F. H. Miller, R. A. Omary et al., “Magnetic resonance elastography and biomarkers to assess fibrosis from recurrent hepatitis c in liver transplant recipients,” Transplantation, vol. 92, no. 5, pp. 581–586, 2011. View at Publisher · View at Google Scholar · View at Scopus
  169. T. J. S. Cross, D. Jothimani, M. A. Heneghan, and P. M. Harrison, “Non-invasive assessment of fibrosis in liver grafts due to hepatitis C virus recurrence,” Clinical Transplantation, vol. 25, no. 3, pp. 345–351, 2011. View at Publisher · View at Google Scholar · View at Scopus
  170. T. J. S. Cross, V. Calvaruso, M. R. Foxton et al., “A simple, noninvasive test for the diagnosis of liver fibrosis in patients with hepatitis C recurrence after liver transplantation,” Journal of Viral Hepatitis, vol. 17, no. 9, pp. 640–649, 2010. View at Publisher · View at Google Scholar · View at Scopus
  171. J. A. Carrión, G. Fernández-Varo, M. Bruguera et al., “Serum fibrosis markers identify patients with mild and progressive hepatitis C recurrence after liver transplantation,” Gastroenterology, vol. 138, no. 1, pp. 147–158, 2010. View at Publisher · View at Google Scholar · View at Scopus
  172. S. Benlloch, L. Heredia, C. Barquero et al., “Prospective validation of a noninvasive index for predicting liver fibrosis in hepatitis C virus-infected liver transplant recipients,” Liver Transplantation, vol. 15, no. 12, pp. 1798–1807, 2009. View at Publisher · View at Google Scholar · View at Scopus
  173. S. Benlloch, M. Berenguer, M. Prieto, J. M. Rayón, V. Aguilera, and J. Berenguer, “Prediction of fibrosis in HCV-infected liver transplant recipients with a simple noninvasive index,” Liver Transplantation, vol. 11, no. 4, pp. 456–462, 2005. View at Publisher · View at Google Scholar · View at Scopus
  174. S. Pungpapong, D. P. Nunes, M. Kirshna et al., “Serum fibrosis markers can predict rapid fibrosis progression after liver transplantation for hepatitis C,” Liver Transplantation, vol. 14, no. 9, pp. 1294–1302, 2008. View at Publisher · View at Google Scholar · View at Scopus
  175. P. Toniutto, C. Fabris, D. Bitetto et al., “Role of AST to platelet ratio index in the detection of liver fibrosis in patients with recurrent hepatitis C after liver transplantation,” Journal of Gastroenterology and Hepatology, vol. 22, no. 11, pp. 1904–1908, 2007. View at Publisher · View at Google Scholar · View at Scopus
  176. B. Roche and D. Samuel, “Hepatitis C virus treatment pre- and post-liver transplantation,” Liver International, vol. 32, supplement 1, pp. 120–128, 2012. View at Google Scholar
  177. J. A. Carrión, E. Martínez-Bauer, G. Crespo et al., “Antiviral therapy increases the risk of bacterial infections in HCV-infected cirrhotic patients awaiting liver transplantation: a retrospective study,” Journal of Hepatology, vol. 50, no. 4, pp. 719–728, 2009. View at Publisher · View at Google Scholar · View at Scopus
  178. X. Forns, M. García-Retortillo, T. Serrano et al., “Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation,” Journal of Hepatology, vol. 39, no. 3, pp. 389–396, 2003. View at Publisher · View at Google Scholar · View at Scopus
  179. J. S. Crippin, T. McCashland, N. Terrault, P. Sheiner, and M. R. Charlton, “A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation,” Liver Transplantation, vol. 8, no. 4, pp. 350–355, 2002. View at Publisher · View at Google Scholar · View at Scopus
  180. G. T. Everson, J. Trotter, L. Forman et al., “Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy,” Hepatology, vol. 42, no. 2, pp. 255–262, 2005. View at Publisher · View at Google Scholar · View at Scopus
  181. R. M. Thomas, J. J. Brems, G. Guzman-Hartman, S. Yong, P. Cavaliere, and D. H. Van Thiel, “Infection with chronic hepatitis C virus and liver transplantation: a role for interferon therapy before transplantation,” Liver Transplantation, vol. 9, no. 9, pp. 905–915, 2003. View at Publisher · View at Google Scholar · View at Scopus
  182. N. A. Terrault, “Prophylactic and preemptive therapies for hepatitis C virus-infected patients undergoing liver transplantation,” Liver Transplantation, vol. 9, no. 11, pp. S95–S100, 2003. View at Publisher · View at Google Scholar · View at Scopus
  183. B. Roche and D. Samuel, “Is early antiviral therapy for recurrent hepatitis C after liver transplantation superior to later treatment? the answer is no,” Liver Transplantation, vol. 17, no. 5, pp. 488–491, 2011. View at Publisher · View at Google Scholar · View at Scopus
  184. G. L. Davis, D. R. Nelson, N. Terrault et al., “A randomized, open-label study to evaluate the safety and pharmacokinetics of human hepatitis C immune globulin (Civacir) in liver transplant recipients,” Liver Transplantation, vol. 11, no. 8, pp. 941–949, 2005. View at Publisher · View at Google Scholar · View at Scopus
  185. T. D. Schiano, M. Charlton, Z. Younossi et al., “Monoclonal antibody HCV-AbXTL68 in patients undergoing liver transplantation for HCV: results of a phase 2 randomized study,” Liver Transplantation, vol. 12, no. 9, pp. 1381–1389, 2006. View at Publisher · View at Google Scholar · View at Scopus
  186. A. K. Shergill, M. Khalili, S. Straley et al., “Applicability, tolerability and efficacy of preemptive antiviral therapy in hepatitis C-infected patients undergoing liver transplantation,” American Journal of Transplantation, vol. 5, no. 1, pp. 118–124, 2005. View at Publisher · View at Google Scholar · View at Scopus
  187. V. Mazzaferro, “Prevention of recurrent hepatitis C after liver transplantation with early interferon and ribavirin treatment,” Transplantation Proceedings, vol. 33, no. 1-2, pp. 1355–1357, 2001. View at Publisher · View at Google Scholar · View at Scopus
  188. S. Tamura, Y. Sugawara, N. Yamashiki, J. Kaneko, N. Kokudo, and M. Makuuchi, “Pre-emptive antiviral therapy in living donor liver transplantation for hepatitis C: observation based on a single-center experience,” Transplant International, vol. 23, no. 6, pp. 580–588, 2010. View at Publisher · View at Google Scholar · View at Scopus
  189. A. Kuo, V. Tan, B. Lan et al., “Long-term histological effects of preemptive antiviral therapy in liver transplant recipients with hepatitis C virus infection,” Liver Transplantation, vol. 14, no. 10, pp. 1491–1497, 2008. View at Publisher · View at Google Scholar · View at Scopus
  190. N. Chalasani, C. Manzarbeitia, P. Ferenci et al., “Peginterferon Alfa-2a for hepatitis C after liver transplantation: two randomized, controlled trials,” Hepatology, vol. 41, no. 2, pp. 289–298, 2005. View at Publisher · View at Google Scholar
  191. N. Singh, T. Gayowski, C. F. Wannstedt et al., “Interferon-α for prophylaxis of recurrent viral hepatitis C in liver transplant recipients: a prospective, randomized, controlled trial,” Transplantation, vol. 65, no. 1, pp. 82–86, 1998. View at Publisher · View at Google Scholar · View at Scopus
  192. N. Bzowej, D. R. Nelson, N. A. Terrault et al., “PHOENIX: a randomized controlled trial of peginterferon alfa-2a plus ribavirin as a prophylactic treatment after liver transplantation for hepatitis C virus,” Liver Transplantation, vol. 17, no. 5, pp. 528–538, 2011. View at Publisher · View at Google Scholar · View at Scopus
  193. M. Berenguer, “Treatment of hepatitis C after liver transplantation,” Clinics in Liver Disease, vol. 9, no. 4, pp. 579–600, 2005. View at Publisher · View at Google Scholar · View at Scopus
  194. C. S. Wang, H. H. Ko, E. M. Yoshida, C. A. Marra, and K. Richardson, “Interferon-based combination anti-viral therapy for hepatitis C virus after liver transplantation: a review and quantitative analysis,” American Journal of Transplantation, vol. 6, no. 7, pp. 1586–1599, 2006. View at Publisher · View at Google Scholar · View at Scopus
  195. M. Berenguer, “Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin,” Journal of Hepatology, vol. 49, no. 2, pp. 274–287, 2008. View at Publisher · View at Google Scholar · View at Scopus
  196. E. Xirouchakis, C. Triantos, P. Manousou et al., “Pegylated-interferon and ribavirin in liver transplant candidates and recipients with HCV cirrhosis: systematic review and meta-analysis of prospective controlled studies,” Journal of Viral Hepatitis, vol. 15, no. 10, pp. 699–709, 2008. View at Publisher · View at Google Scholar · View at Scopus
  197. P. Guillouche and C. Féray, “Systematic review: anti-viral therapy of recurrent hepatitis C after liver transplantation,” Alimentary Pharmacology and Therapeutics, vol. 33, no. 2, pp. 163–174, 2011. View at Publisher · View at Google Scholar · View at Scopus
  198. K. S. Gurusamy, E. Tsochatzis, B. R. Davidson, and A. K. Burroughs, “Antiviral prophylactic intervention for chronic hepatitis C virus in patients undergoing liver transplantation,” Cochrane Database of Systematic Reviews, vol. 12, Article ID CD006573, 2010. View at Google Scholar · View at Scopus
  199. H. Rodriguez-Luna, A. Khatib, P. Sharma et al., “Treatment of recurrent hepatitis C infection after liver transplantation with combination of pegylated interferon α2b and ribavirin: an open-label series,” Transplantation, vol. 77, no. 2, pp. 190–194, 2004. View at Publisher · View at Google Scholar · View at Scopus
  200. G. W. Neff, M. Montalbano, C. B. O'Brien et al., “Treatment of established recurrent hepatitis C in liver-transplant recipients with pegylated interferon-alfa-2b and ribavirin therapy,” Transplantation, vol. 78, no. 9, pp. 1303–1307, 2004. View at Publisher · View at Google Scholar · View at Scopus
  201. A. S. Ross, A. K. Bhan, M. Pascual, M. Thiim, A. B. Cosimi, and R. T. Chung, “Pegylated interferon α-2b plus ribavirin in the treatment of post-liver transplant recurrent hepatitis C,” Clinical Transplantation, vol. 18, no. 2, pp. 166–173, 2004. View at Publisher · View at Google Scholar · View at Scopus
  202. J. Dumortier, J. Y. Scoazec, P. Chevallier, and O. Boillot, “Treatment of recurrent hepatitis C after liver transplantation: a pilot study of peginterferon alfa-2b and ribavirin combination,” Journal of Hepatology, vol. 40, no. 4, pp. 669–674, 2004. View at Publisher · View at Google Scholar · View at Scopus
  203. M. Babatin, L. Schindel, and K. W. Burak, “Pegylated-interferon alpha 2b and ribavirin for recurrent hepatities C after liver liver transplantation: from a Canadian experience to recommendations for therapy,” Canadian Journal of Gastroenterology, vol. 19, no. 6, pp. 359–365, 2005. View at Google Scholar · View at Scopus
  204. P. Toniutto, C. Fabris, E. Fumo et al., “Pegylated versus standard interferon-α in antiviral regimens for post-transplant recurrent hepatitis C: comparison of tolerability and efficacy,” Journal of Gastroenterology and Hepatology, vol. 20, no. 4, pp. 577–582, 2005. View at Publisher · View at Google Scholar · View at Scopus
  205. L. Castells, V. Vargas, H. Allende et al., “Combined treatment with pegylated interferon (α-2b) and ribavirin in the acute phase of hepatitis C virus recurrence after liver transplantation,” Journal of Hepatology, vol. 43, no. 1, pp. 53–59, 2005. View at Publisher · View at Google Scholar · View at Scopus
  206. M. Biselli, P. Andreone, A. Gramenzi et al., “Pegylated interferon plus ribavirin for recurrent Hepatitis C infection after liver transplantation in naïve and non-responder patients on a stable immunosuppressive regimen,” Digestive and Liver Disease, vol. 38, no. 1, pp. 27–32, 2006. View at Publisher · View at Google Scholar · View at Scopus
  207. M. Berenguer, A. Palau, A. Fernandez et al., “Efficacy, predictors of response, and potential risks associated with antiviral therapy in liver transplant recipients with recurrent hepatitis C,” Liver Transplantation, vol. 12, no. 7, pp. 1067–1076, 2006. View at Publisher · View at Google Scholar · View at Scopus
  208. E. Oton, R. Barcena, J. M. Moreno-Planas et al., “Hepatitis C recurrence after liver transplantation: viral and histologic response to full-dose peg-interferon and ribavirin,” American Journal of Transplantation, vol. 6, no. 10, pp. 2348–2355, 2006. View at Publisher · View at Google Scholar · View at Scopus
  209. S. Mukherjee and E. Lyden, “Impact of pegylated interferon α-2B and ribavirin on hepatic fibrosis in liver transplant patients with recurrent hepatitis C: an open-label series,” Liver International, vol. 26, no. 5, pp. 529–535, 2006. View at Publisher · View at Google Scholar · View at Scopus
  210. S. Mukherjee and E. Lyden, “Impact of pegylated interferon alfa-2a and ribavirin on hepatic fibrosis in liver transplant patients with recurrent hepatitis C: an open-label series,” Hepato-Gastroenterology, vol. 53, no. 70, pp. 561–565, 2006. View at Google Scholar · View at Scopus
  211. I. Fernández, J. C. Meneu, F. Colina et al., “Clinical and histological efficacy of pegylated interferon and ribavirin therapy of recurrent hepatitis C after liver transplantation,” Liver Transplantation, vol. 12, no. 12, pp. 1805–1812, 2006. View at Publisher · View at Google Scholar · View at Scopus
  212. U. Neumann, G. Puhl, M. Bahra et al., “Treatment of patients with recurrent hepatitis C after liver transplantation with peginterferon alfa-2B plus ribavirin,” Transplantation, vol. 82, no. 1, pp. 43–47, 2006. View at Publisher · View at Google Scholar · View at Scopus
  213. F. P. Picciotto, G. Tritto, A. G. Lanza et al., “Sustained virological response to antiviral therapy reduces mortality in HCV reinfection after liver transplantation,” Journal of Hepatology, vol. 46, no. 3, pp. 459–465, 2007. View at Publisher · View at Google Scholar · View at Scopus
  214. M. Angelico, A. Petrolati, R. Lionetti et al., “A randomized study on Peg-interferon alfa-2a with or without ribavirin in liver transplant recipients with recurrent hepatitis C,” Journal of Hepatology, vol. 46, no. 6, pp. 1009–1017, 2007. View at Publisher · View at Google Scholar · View at Scopus
  215. J. A. Carrión, M. Navasa, M. García-Retortillo et al., “Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study,” Gastroenterology, vol. 132, no. 5, pp. 1746–1756, 2007. View at Publisher · View at Google Scholar · View at Scopus
  216. P. Sharma, J. A. Marrero, R. J. Fontana et al., “Sustained virologic response to therapy of recurrent hepatitis C after liver transplantation is related to early virologic response and dose adherence,” Liver Transplantation, vol. 13, no. 8, pp. 1100–1108, 2007. View at Publisher · View at Google Scholar · View at Scopus
  217. T. Zimmermann, W. O. Böcher, S. Biesterfeld et al., “Efficacy of an escalating dose regimen of pegylated interferon α-2a plus ribavirin in the early phase of HCV reinfection after liver transplantation,” Transplant International, vol. 20, no. 7, pp. 583–590, 2007. View at Publisher · View at Google Scholar · View at Scopus
  218. S. Dinges, I. Morard, M. Heim et al., “Pegylated interferon-alpha2a/ribavirin treatment of recurrent hepatitis C after liver transplantation,” Transplant Infectious Disease, vol. 11, no. 1, pp. 33–39, 2009. View at Publisher · View at Google Scholar · View at Scopus
  219. F. Lodato, S. Berardi, A. Gramenzi et al., “Clinical trial: peg-interferon alfa-2b and ribavirin for the treatment of genotype-1 hepatitis C recurrence after liver transplantation,” Alimentary Pharmacology and Therapeutics, vol. 28, no. 4, pp. 450–457, 2008. View at Publisher · View at Google Scholar · View at Scopus
  220. I. A. Hanouneh, C. Miller, F. N. Aucejo, R. Lopez, M. K. Quinn, and N. N. Zein, “Recurrent hepatitis C after liver transplantation: ON-treatment prediction of response to peginterferon/ribavirin therapy,” Liver Transplantation, vol. 14, no. 1, pp. 53–58, 2008. View at Publisher · View at Google Scholar · View at Scopus
  221. S. C. Schmidt, M. Bahra, S. Bayraktar et al., “Antiviral treatment of patients with recurrent hepatitis c after liver transplantation with pegylated interferon,” Digestive Diseases and Sciences, vol. 55, no. 7, pp. 2063–2069, 2010. View at Publisher · View at Google Scholar · View at Scopus
  222. A. Jain, R. Sharma, C. Ryan et al., “Response to antiviral therapy in liver transplant recipients with recurrent hepatitis C viral infection: a single center experience,” Clinical Transplantation, vol. 24, no. 1, pp. 104–111, 2010. View at Publisher · View at Google Scholar · View at Scopus
  223. W. Al-Hamoudi, H. Mohamed, F. Abaalkhail et al., “Treatment of genotype 4 hepatitis C recurring after liver transplantation using a combination of pegylated interferon alfa-2a and ribavirin,” Digestive Diseases and Sciences, vol. 56, no. 6, pp. 1848–1852, 2011. View at Publisher · View at Google Scholar · View at Scopus
  224. P. J. Gaglio, S. Malireddy, B. S. Levitt et al., “Increased risk of cholestatic hepatitis C in recipients of grafts from living versus cadaveric liver donors,” Liver Transplantation, vol. 9, no. 10, pp. 1028–1035, 2003. View at Publisher · View at Google Scholar · View at Scopus
  225. M. Garcia-Retortillo, X. Forns, J. M. Llovet et al., “Hepatitis C recurrence is more severe after living donor compared to cadaveric liver transplantation,” Hepatology, vol. 40, no. 3, pp. 699–707, 2004. View at Publisher · View at Google Scholar · View at Scopus
  226. D. G. Maluf, R. T. Stravitz, A. H. Cotterell et al., “Adult living donor versus deceased donor liver transplantation: a 6-year single center experience,” American Journal of Transplantation, vol. 5, no. 1, pp. 149–156, 2005. View at Publisher · View at Google Scholar · View at Scopus
  227. P. J. Thuluvath and H. Y. Yoo, “Graft and patient survival after adult live donor liver transplantation compared to a matched cohort who received a deceased donor transplantation,” Liver Transplantation, vol. 10, no. 10, pp. 1263–1268, 2004. View at Publisher · View at Google Scholar · View at Scopus
  228. M. W. Russo, J. Galanko, K. Beavers, M. W. Fried, and R. Shrestha, “Patient and graft surivival in hepatitis C recipients after adult living donor liver transplantation in the United States,” Liver Transplantation, vol. 10, no. 3, pp. 340–346, 2004. View at Publisher · View at Google Scholar · View at Scopus
  229. A. Bozorgzadeh, A. Jain, C. Ryan et al., “Impact of hepatitis C viral infection in primary cadaveric liver allograft versus primary living-donor allograft in 100 consecutive liver transplant recipients receiving tacrolimus,” Transplantation, vol. 77, no. 7, pp. 1066–1070, 2004. View at Publisher · View at Google Scholar
  230. H. Van Vlierberghe, R. Troisi, I. Colle, S. Ricciardi, M. Praet, and B. De Hemptinne, “Hepatitis C infection-related liver disease: patterns of recurrence and outcome in cadaveric and living-donor liver transplantation in adults,” Transplantation, vol. 77, no. 2, pp. 210–214, 2004. View at Publisher · View at Google Scholar · View at Scopus
  231. T. D. Schiano, J. A. Gutierrez, J. L. Walewski et al., “Accelerated hepatitis C virus kinetics but similar survival rates in recipients of liver grafts from living versus deceased donors,” Hepatology, vol. 42, no. 6, pp. 1420–1428, 2005. View at Publisher · View at Google Scholar · View at Scopus
  232. N. Selzner, N. Girgrah, L. Lilly et al., “The difference in the fibrosis progression of recurrent hepatitis C after live donor liver transplantation versus deceased donor liver transplantation is attributable to the difference in donor age,” Liver Transplantation, vol. 14, no. 12, pp. 1778–1786, 2008. View at Publisher · View at Google Scholar · View at Scopus
  233. A. Jain, A. Singhal, R. Kashyap, S. Safadjou, C. K. Ryan, and M. S. Orloff, “Comparative analysis of hepatitis C recurrence and fibrosis progression between deceased-donor and living-donor liver transplantation: 8-year longitudinal follow-up,” Transplantation, vol. 92, no. 4, pp. 453–460, 2011. View at Publisher · View at Google Scholar · View at Scopus
  234. M. Cescon, G. L. Grazi, A. Cucchetti et al., “Predictors of sustained virological response after antiviral treatment for hepatitis C recurrence following liver transplantation,” Liver Transplantation, vol. 15, no. 7, pp. 782–789, 2009. View at Publisher · View at Google Scholar · View at Scopus
  235. B. Raziorrouh, M. C. Jung, C. A. Schirren et al., “Antiviral therapy for recurrent hepatitis C after liver transplantation: sustained virologic response is related to genotype 2/3 and response at week 12,” European Journal of Gastroenterology and Hepatology, vol. 20, no. 8, pp. 778–783, 2008. View at Publisher · View at Google Scholar · View at Scopus
  236. M. Berenguer, C. Ortíz-Cantó, J. J. Abellán et al., “Hepatitis C virus viral kinetics during α-2a or α-2b pegylated interferon plus ribavirin therapy in liver transplant recipients with different immunosuppression regimes,” Journal of Clinical Virology, vol. 53, no. 3, pp. 231–238, 2012. View at Publisher · View at Google Scholar
  237. T. Walter, J. Y. Scoazec, O. Guillaud et al., “Long-term antiviral therapy for recurrent hepatitis C after liver transplantation in nonresponders: biochemical, virological, and histological impact,” Liver Transplantation, vol. 15, no. 1, pp. 54–63, 2009. View at Publisher · View at Google Scholar · View at Scopus
  238. B. J. Veldt, J. J. Poterucha, K. D. S. Watt et al., “Impact of pegylated interferon and ribavirin treatment on graft survival in liver transplant patients with recurrent hepatitis C infection,” American Journal of Transplantation, vol. 8, no. 11, pp. 2426–2433, 2008. View at Publisher · View at Google Scholar · View at Scopus
  239. M. Berenguer, A. Palau, V. Aguilera, J. M. Rayón, F. S. Juan, and M. Prieto, “Clinical benefits of antiviral therapy in patients with recurrent hepatitis C following liver transplantation,” American Journal of Transplantation, vol. 8, no. 3, pp. 679–687, 2008. View at Publisher · View at Google Scholar · View at Scopus
  240. D. Samuel, T. Bizollon, C. Feray et al., “Interferon-α 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study,” Gastroenterology, vol. 124, no. 3, pp. 642–650, 2003. View at Publisher · View at Google Scholar · View at Scopus
  241. R. T. Stravitz, M. L. Shiffman, A. J. Sanyal et al., “Effects of interferon treatment on liver histology and allograft rejection in patients with recurrent hepatitis C following liver transplantation,” Liver Transplantation, vol. 10, no. 7, pp. 850–858, 2004. View at Publisher · View at Google Scholar · View at Scopus
  242. M. Kugelmas, M. J. Osgood, J. F. Trotter et al., “Hepatitis C virus therapy, hepatocyte drug metabolism, and risk for acute cellular rejection,” Liver Transplantation, vol. 9, no. 11, pp. 1159–1165, 2003. View at Publisher · View at Google Scholar · View at Scopus
  243. C. M. Stanca, M. I. Fiel, N. Kontorinis, K. Agarwal, S. Emre, and T. D. Schiano, “Chronic ductopenic rejection in patients with recurrent hepatitis C virus treated with pegylated interferon alfa-2a and ribavirin,” Transplantation, vol. 84, no. 2, pp. 180–186, 2007. View at Publisher · View at Google Scholar · View at Scopus
  244. N. Selzner, M. Guindi, E. L. Renner, and M. Berenguer, “Immune-mediated complications of the graft in interferon-treated hepatitis C positive liver transplant recipients,” Journal of Hepatology, vol. 55, no. 1, pp. 207–217, 2011. View at Publisher · View at Google Scholar · View at Scopus
  245. E. Cholongitas, D. Samonakis, D. Patch et al., “Induction of autoimmune hepatitis by pegylated interferon in a liver transplant patient with recurrent hepatitis C virus,” Transplantation, vol. 81, no. 3, pp. 488–490, 2006. View at Publisher · View at Google Scholar · View at Scopus
  246. N. Kontorinis, K. Agarwal, N. Elhajj, M. I. Fiel, and T. D. Schiano, “Pegylated interferon-induced immune-mediated hepatitis post-liver transplantation,” Liver Transplantation, vol. 12, no. 5, pp. 827–830, 2006. View at Publisher · View at Google Scholar · View at Scopus
  247. S. Berardi, F. Lodato, A. Gramenzi et al., “High incidence of allograft dysfunction in liver transplanted patients treated with pegylated-interferon alpha-2b and ribavirin for hepatitis C recurrence: possible de novo autoimmune hepatitis?” Gut, vol. 56, no. 2, pp. 237–242, 2007. View at Publisher · View at Google Scholar · View at Scopus
  248. T. Asselah and P. Marcellin, “New direct-acting antivirals' combination for the treatment of chronic hepatitis C,” Liver International, vol. 31, no. 1, pp. 68–77, 2011. View at Publisher · View at Google Scholar · View at Scopus
  249. V. Garg, R. van Heeswijk, J. Eun Lee, K. Alves, P. Nadkarni, and X. Luo, “Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus,” Hepatology, vol. 54, no. 1, pp. 20–27, 2011. View at Publisher · View at Google Scholar · View at Scopus
  250. M. Charlton, “Telaprevir, boceprevir, cytochrome P450 and immunosuppressive agents—a potentially lethal cocktail,” Hepatology, vol. 54, no. 1, pp. 3–5, 2011. View at Publisher · View at Google Scholar · View at Scopus
  251. N. Fausto and J. S. Campbell, “The role of hepatocytes and oval cells in liver regeneration and repopulation,” Mechanisms of Development, vol. 120, no. 1, pp. 117–130, 2003. View at Publisher · View at Google Scholar · View at Scopus
  252. M. A. Zimmerman and J. F. Trotter, “Living donor liver transplantation in patients with hepatitis C,” Liver Transplantation, vol. 9, no. 11, pp. S52–S57, 2003. View at Publisher · View at Google Scholar · View at Scopus
  253. K. M. Olthoff, “Hepatic regeneration in living donor liver transplantation,” Liver Transplantation, vol. 9, no. 10, pp. S35–S41, 2003. View at Google Scholar · View at Scopus
  254. G. T. Everson and J. Trotter, “Role of adult living donor liver transplantation in patients with hepatitis C,” Liver Transplantation, vol. 9, no. 10, supplement, pp. S64–S68, 2003. View at Google Scholar · View at Scopus
  255. R. Manez, R. Mateo, J. Tabasco, S. Kusne, T. E. Starzl, and R. J. Duquesnoy, “The influence of HLA donor-recipient compatibility on the recurrence of HBV and HCV hepatitis after liver transplantation,” Transplantation, vol. 59, no. 4, pp. 640–642, 1995. View at Google Scholar · View at Scopus
  256. J. A. Carrión, M. Navasa, and X. Forns, “Retransplantation in patients with hepatitis C recurrence after liver transplantation,” Journal of Hepatology, vol. 53, no. 5, pp. 962–970, 2010. View at Publisher · View at Google Scholar · View at Scopus
  257. H. Y. Yoo, A. Maheshwari, and P. J. Thuluvath, “Retransplantation of liver: primary graft nonfunction and hepatitis C virus are associated with worse outcome,” Liver Transplantation, vol. 9, no. 9, pp. 897–904, 2003. View at Publisher · View at Google Scholar · View at Scopus
  258. G. W. Neff, C. B. O'Brien, J. Nery et al., “Factors that identify survival after liver retransplantation for allograft failure caused by recurrent hepatitis C infection,” Liver Transplantation, vol. 10, no. 12, pp. 1497–1503, 2004. View at Publisher · View at Google Scholar · View at Scopus
  259. S. J. Pelletier, D. E. Schaubel, J. D. Punch, R. A. Wolfe, F. K. Port, and R. M. Merion, “Hepatitis C is a risk factor for death after liver retransplantation,” Liver Transplantation, vol. 11, no. 4, pp. 434–440, 2005. View at Publisher · View at Google Scholar · View at Scopus
  260. S. Roayaie, T. D. Schiano, S. N. Thung et al., “Results of retransplantation for recurrent hepatitis C,” Hepatology, vol. 38, no. 6, pp. 1428–1436, 2003. View at Publisher · View at Google Scholar · View at Scopus
  261. H. R. Rosen, J. P. Madden, and P. Martin, “A model to predict survival following liver retransplantation,” Hepatology, vol. 29, no. 2, pp. 365–370, 1999. View at Publisher · View at Google Scholar · View at Scopus
  262. F. Y. Yao, S. Saab, N. M. Bass et al., “Prediction of survival after liver retransplantation for late graft failure based on preoperative prognostic scores,” Hepatology, vol. 39, no. 1, pp. 230–238, 2004. View at Publisher · View at Google Scholar · View at Scopus
  263. T. McCashland, K. Watt, E. Lyden et al., “Retransplantation for hepatitis C: results of a U.S. multicenter retransplant study,” Liver Transplantation, vol. 13, no. 9, pp. 1246–1253, 2007. View at Publisher · View at Google Scholar · View at Scopus
  264. H. R. Rosen, M. Prieto, T. Casanovas-Taltavull et al., “Validation and refinement of survival models for liver retransplantation,” Hepatology, vol. 38, no. 2, pp. 460–469, 2003. View at Publisher · View at Google Scholar · View at Scopus
  265. K. D. S. Watt, E. R. Lyden, and T. M. McCashland, “Poor survival after liver retransplantation: is hepatitis C to blame?” Liver Transplantation, vol. 9, no. 10, pp. 1019–1024, 2003. View at Publisher · View at Google Scholar · View at Scopus
  266. J. Martí, R. Charco, J. Ferrer et al., “Optimization of liver grafts in liver retransplantation: a European single-center experience,” Surgery, vol. 144, no. 5, pp. 762–769, 2008. View at Publisher · View at Google Scholar · View at Scopus
  267. P. G. Northup, T. L. Pruett, D. M. Kashmer, C. K. Argo, C. L. Berg, and T. M. Schmitt, “Donor factors predicting recipient survival after liver retransplantation: the retransplant donor risk index,” American Journal of Transplantation, vol. 7, no. 8, pp. 1984–1988, 2007. View at Publisher · View at Google Scholar · View at Scopus